Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Ilmiah Farmasi Prosiding University Research Colloquium
Ramadhan, Viren
Unknown Affiliation
Humanities Computer Science & IT Environmental Science Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
PERBANDINGAN EFEKTIVITAS TERAPI DAN BIAYA FILGRASTIM DAN LENOGRASTIM PADA PASIEN KANKER KOLOREKTAL DENGAN REGIMEN KEMOTERAPI FOLFOX Pratama, Jainuri Erik; Ramadhan, Viren; Saharuddin; Pahlavi, Ridlo
Jurnal Ilmiah Farmasi Vol. 20 No. 2 (2024): Jurnal Ilmiah Farmasi
Publisher : Universitas Islam Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20885/jif.vol20.iss2.art10

Abstract

Background: Granulocyte colony-stimulating factor (GCSF) is a primary regulator of the granulopoiesis process, which mobilizes stem cells from the bone marrow to the blood vessels. Filgrastim and lenograstim are the types of GCSF that have been widely used. Objective: This research aims to study the comparative therapeutic outcomes and cost-effectiveness of filgrastim and lenograstim therapies in colorectal cancer patients undergoing chemotherapy with the FOLFOX regimen.Method: This research was conducted at the pharmacy installation of the Dr. Kariadi Central General Hospital (RSUP Dr. Kariadi) from December 2023 to January 2024. It is observational research with a retrospective pre-posttest cohort study design that evaluates the comparative effectiveness and costs of filgrastim and lenograstim therapies in patients with neutropenia based on an increase in white blood cells (WBC) and absolute neutrophil count (ANC) scores of patients. The data was analyzed using the unpaired comparative analysis method and using the cost-effectiveness analysis (CEA) method to determine the cost-effectiveness. The observations were carried out twice, before and after administering the GCSF therapy. The samples consisted of 25 patients divided into two treatment groups. Results: The average scores of WBC and ANC levels in 15 patients who received filgrastim therapy were 2000 cells/mm3 and 666 cells/mm3. At the same time, the WBC and ANC levels in 10 patients who received lenograstim therapy were 1980 cells/mm3 and 449 cells/mm3. After administering the GCSF therapy, there was a significant increase in WBC and ANC levels (p<0.05) in each group. Still, there was no significant difference in the increase in WBC and ANC between the groups receiving filgrastim and lenograstim (p>0.05). The CEA analysis results showed that an increase of 1 cell/ml of WBC score cost Rp24.2 for filgrastim and Rp347 for lenograstim. In contrast, an increase of 1 cell/ml of ANC score cost Rp111.8 for filgrastim and Rp1572.5 for lenograstim.Conclusion: This research concludes that filgrastim is as effective as lenograstim, yet filgrastim is considered more cost-effective than lenograstim.
Evaluasi Rasionalitas Bronkodilator pada Pasien Asma di Puskesmas Purwosari Kudus Ramadhan, Viren; Arwani, Rizka; Huda, Nurul; Septiyaningrum, Dewi
Prosiding University Research Colloquium Proceeding of The 13th University Research Colloquium 2021: Kesehatan dan MIPA
Publisher : Konsorsium Lembaga Penelitian dan Pengabdian kepada Masyarakat Perguruan Tinggi Muhammadiyah 'Aisyiyah (PTMA) Koordinator Wilayah Jawa Tengah - DIY

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Asma merupakan penyakit saluran napas kronis yang ditandai dengan sesak napas berulang disertai mengi dengan frekuensi dan tingkat keparahan bervariasi pada setiap orang. Penatalaksaan terapi yang rasional harus dilakukan agar berdampak positif pada pasien. Penelitian ini bertujuan untuk mengetahui profil dan rasionalitas penggunaan bronkodilator pada pasien asma di Puskesmas Purwosari, Kudus. Penilitian observasional deskriptif dengan pendekatan retrospective. Sebanyak 34 pasien diikutkan dalam penelitian ini dengan mengambil data sekunder dari rekam medis. Diperoleh hasil bahwa pasien berusia 45-66 tahun (35.3%) yang mayoritasnya ialah perempuan (70.6%). Tingkat rasionalitas meliputi tepat indikasi, tepat pasien, tepat obat, dan tepat dosis masing-masin 100%. Dapat disimpulkan bahwa penggunaan bronkodilator pada pasien asma di Puskesmas Purwosari sudah rasional.
Co-Authors Arwani, Rizka Nurul Huda Pahlavi, Ridlo Pratama, Jainuri Erik Saharuddin Septiyaningrum, Dewi